UVC-360

BETR-D Study Shows 11% C. diff Reduction

Posted by Tru-D SmartUVC 04.26.17

The Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study is the first and only randomized clinical trial on UV disinfection.

The BETR-D’s primary outcome showed that enhanced terminal room disinfection strategies using Tru-D decreased the relative risk of colonization and infection of target MDROs among patients admitted to the same room by a cumulative 30 percent in a hospital setting with 93 percent compliance of standard disinfection protocols.

Individual hospital results may vary based on numerous factors including adherence to standard disinfection protocol.

A new analysis of the BETR-D study showed that enhanced terminal room disinfection with Tru-D SmartUVC leads to a decrease in incidence of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide. The results were based on 93 percent compliance of standard disinfection protocols, and individual hospital results may vary.

 

Hospitals face challenges every day with infections. Tru-D adds a layer of protection in the disinfection process to help keep patients and staffs safe. Contact us at info@tru-d.com to see how we can help build a business case for cost avoidance with Tru-D at your hospital.  

Posted 04.26.17
  • Share

Never miss the latest in UV news.
Subscribe to UVC360 today.

Sign Up »